© AzurPharma Ltd.
Company Number 399192
Dublin, Ireland, March 9, 2007 - Azur Pharma Limited ("Azur") today announced that Mr. Anthony Tebbutt has joined its Board of Directors.
Mr. Tebbutt has held various senior level sales, marketing and executive management positions in the pharmaceutical industry. Most recently he was President of UCB Inc. ("UCB"), the U.S. affiliate of the global Belgian biopharmaceutical company. During his 10 year tenure at UCB, its U.S. pharmaceutical revenues grew tenfold to over $1 billion. He oversaw the launch of Keppra® (levetiracetam) which is today a leading therapy in epilepsy, and several co-promotions most noticeably the partnership with Pfizer Inc. on Zyrtec® (cetirizine HCl). Prior to joining UCB, Mr. Tebbutt worked at Eli Lilly and Company, and Syntex Corporation. Mr. Tebbutt holds a Bachelor of Science from Santa Clara University and a MBA from Stanford University. He has served as a board member of various Pharma industry organizations including the National Pharmaceutical Council and the Georgia Biomedical Partnership.
"Tony will make an important contribution as a Director of Azur as we enter a phase of rapid growth and investment. His experience in managing this type of growth while at UCB, and extensive industry experience and contacts, will be extremely valuable to the company", commented Mr. Seamus Mulligan, Azur Pharma's Chairman and Chief Executive Officer.
In addition, Azur today announced that Gil Golden, MD, PhD, and Matt Wiley have been appointed Senior Director of Medical Affairs and Senior Director of Marketing, respectively. Dr. Golden was most recently Director of Medical Affairs for Pharmion Corporation and previously was Director of Medical Affairs for Guilford Pharmaceuticals Inc. Mr. Wiley was most recently Director of Marketing for MGI Pharma Inc and previously was a senior marketing manager for Salix Pharmaceuticals Inc.
"I welcome Gil and Matt to Azur. Gil and Matt strengthen our U.S. medical and marketing infrastructure and will add considerable value to our current products and future diligence and acquisition activities", said Mr. Mulligan.
About Azur Pharma
Azur Pharma is a privately held pharmaceutical company dedicated to enhancing patients’ lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur Pharma’s strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development and approved pharmaceutical products.
Website
www.azurpharma.com
Azur Pharma Ltd,
45 Fitzwilliam Square,
Dublin 2, Ireland.
Tel: +353-1-6344-183
Fax:+353-1-6344-170
www.azurpharma.com